Pharmaceutical company Corcept Therapeutics Inc. Friday said it has submitted a New Drug Application or NDA for the use of Corlux in Cushing's Syndrome to the US Food and Drug Administration or FDA.
52550
Corcept Therapeutics submits NDA for the use of Corlux in Cushing's Syndrome
124569
BioAlliance Pharma announces the
112374
AdnaGen enters into agreement to license antibodies to KellBenx
48195
Medtronic assigned patent for medical device sensing and detection during MRI
28320
Incyte enters into collaboration and license agreement with Novartis
106228
Merus Labs announces execution of binding letter of intent for the licensing, registration and distribution of specific pharmaceutical products and medical devices in Canada
150113
Boston Scientific receives CE Mark approval for spinal cord stimulator system
133645
Wockhardt received tentative approval for the Fexofenadine Hydrochloride
140546
Roche receives request for additional information from the Federal Trade Commission
98476
Genzyme files applications for approval of Mozobil in the US, European Union
129407
E-Therapeutics granted US patent for key process
69958
Alimera Sciences resubmits new drug application
101804
``Love'' hormone appears to help familiar faces:
170645
Syntroleum assigned patent
9428
Wockhardt launches nicardipine injections in US
134739
Watson Pharmaceuticals receives FDA approval for oral contraceptive product
63919
Angiogenesis inhibitor formulated through nanotechnology shows promising anticancer results